Efficacy of moxifloxacin in the treatment of secondary peritonitis

Antibiotiki i Khimioterapiya

Volumn 51, Issue 5, 2006, Pages 3-10

  Yakovlev, S V ^a   Ramishvili, V Sh ^a   Nazarov, V V ^a   Eremina, L V ^a  

^a NONE

Author keywords

Clinical and bacteriological efficacy; Monotherapy; Moxifloxacin; Pathogens; Secondary peritonitis

Indexed keywords

ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; QUINOLINE DERIVATIVE;

ADULT; AGED; APACHE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PERITONITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFECTIVE AGENTS; APACHE; AZA COMPOUNDS; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PERITONITIS; QUINOLINES; TREATMENT OUTCOME;

ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI;

EID: 33846609952     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Meakins J. L., Solomkin J. S., Allo M. D. et al. A proposed classification of intra-abdominal infections: stratification of etiology and risk for future therapeutic trials. Arch Surg 1984; 119: 1372-1378.
2. Solomkin J. S., Mazuski J. E., Baron E. J. et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
3. Finegold S. M. Abdominal and peritoneal infections /Anaerobic bacteria in human disease. Finegold S. M. ed. New York, 1977: 257-313.
4. Gorbach S. L., Thadepalli H., Norsen J. et al. Anaerobic microorganisms in intra-abdominal infections. / Anaerobic bacteria: role in disease. Balows A., de Haan R. M., Dowell V. R. et al., eds. London, 1974: 399-407.
5. Altemeier W. A. The bacterial flora of acute perforated appendicitis with peritonitis. Ann Surg 1938; 107: 517-528.
6. Swenson R. M., Lorber B., Michaelson T. C. et al. The bacteriology of intra-abdominal infections. Ibid; 1974; 109: 389-398.
7. Bennion R. S., Thompson J. L., Baron E. L. et al. Gangrenous and perforated appendicitis with peritonitis: treatment and bacteriology. Clin Ther 1990; 12: Suppl C: 31-44.
8. Mazuski J. E., Sawyer R. G., Nathens A. B. et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect 2002; 3: 3: 161-173.
9. Soussy C. J., Nguyen J., Goldstein F. et al. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. Clin Microbiol Infect 2003; 9: 10: 997-1005.
10. Ambler J. E., Choudhri S. H., Haverstock D. et al. Moxifloxacin in vitro activity against non-pneumococcal streptococci isolated from six recent clinical studies {abstr #P1301]. 16th Eur Congr Clin Microbiol Infect Dis, April 1-4, 2006. Nice.
11. Edmistone C. E., Krepel J. K., Seabrook G. R. et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48: 1012-1016.
12. Thadepalli H., Chuah S. K., Gollapudi S. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice. Chemotherapy 2004; 50: 2: 76-80.
13. Hermsen E. D., Hovde L. B., Sprandel K. A. et al. Moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2005; 49: 685-689.
14. Schaumann R., Blatz R., Beer J. et al. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli. J Antimicrob Chemother 2004; 53: 2: 318-324.
15. Stass H., Rink A. D., Delesen H. et al. Pharmacokinetics of moxifloxacin in tissues of the CI-tract [Abstr #O359]. 16th Eur Congr Clin Microbiol Infect Dis, April 1-4, 2006. Nice.
16. Schwab D., Grauer M., Hahn E. G., Muhldorfer S. Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract. Aliment Pharmacol Ther. 2005; 22: 5: 417-422.
17. Malangoni M., Song J., Choudhri S. et al. Sequential IV/PO moxifloxacin versus IV piperacillin/tazobactam +/- PO amoxicillin/clavulanate for treatment of complicated intra-abdominal infections. 44th Intersci Conf Antimicrob Agents Chemother, Oct 30 - Nov 2. Washington, 2004; Abstr #402710.